Inari Medical plans to pay up to $415m for Paris-based LimFlow SA to add the LimFlow transcatheter deep-vein arterialization system to its portfolio of peripheral vascular interventional devices, the companies announced on 1 November.
“Our ethos and mission are focused on addressing significant unmet needs and thinking big,” Inari CEO Andrew Hykes said during Inari’s third-quarter 2023 earnings calls on 1 November
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?